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Abstract
The role of the PEA3 subfamily of Ets transcription factors in breast neoplasia is controversial. Although overexpression of
PEA3 (E1AF/ETV4), and of the related factors ERM (ETV5) and ER81 (ETV1), have been observed in human and mouse breast
tumors, PEA3 factors have also been ascribed a tumor suppressor function. Here, we utilized the MMTV/Wnt1 mouse strain
to further interrogate the role of PEA3 transcription factors in mammary tumorigenesis based on our previous observation
that Pea3 is highly expressed in MMTV/Wnt1 mammary tumors. Pea3 expression in mouse mammary tissues was visualized
using a Pea3
NLSlacZ reporter strain. In normal mammary glands, Pea3 expression is predominantly confined to myoepithelial
cells. Wnt1 transgene expression induced marked amplification of this cell compartment in nontumorous mammary glands,
accompanied by an apparent increase in Pea3 expression. The pattern of Pea3 expression in MMTV/Wnt1 mammary glands
recapitulated the cellular profile of activated b-catenin/TCF signaling, which was visualized using both b-catenin
immunohistochemistry and the b-catenin/TCF-responsive reporter Axin2
NLSlacZ. To test the requirement for PEA3 factors in
Wnt1-induced tumorigenesis, we employed a mammary-targeted dominant negative PEA3 transgene, DNPEA3En.
Expression of DNPEA3En delayed early-onset tumor formation in MMTV/Wnt1 virgin females (P=0.03), suggesting a
requirement for PEA3 factor function for Wnt1-driven tumor formation. Consistent with this observation, expression of the
DNPEA3En transgene was profoundly reduced in mammary tumors compared to nontumorous mammary glands from
bigenic MMTV/Wnt1, MMTV/DNPEA3En mice (P=0.01). Our data provide the first description of Wnt1-mediated expansion
of the Pea3-expressing myoepithelial compartment in nontumorous mammary glands. Consistent with this observation,
mammary myoepithelium was selectively responsive to Wnt1. Together these data suggest the MMTV/Wnt1 strain as a
potential model of basal breast cancer. Furthermore, this study provides evidence for a protumorigenic role of PEA3 factors
in breast neoplasia, and supports targeting the PEA3 transcription factor family in breast cancer.
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Introduction
The mammalian Ets transcription factor superfamily comprises
around 26 proteins characterized by highly related DNA-binding
domains containing winged-helix-turn-helix motifs [1–3]. Ets
factors regulate transcription through binding of this ETS DNA
binding domain directly to Ets binding sites in the promoters of
target genes. The Ets factor PEA3 (also called E1AF and ETV4)
was originally identified through its ability to bind a motif in the
polyomavirus enhancer and mediate oncogene-dependent activa-
tion, and was subsequently assigned to a subfamily of three closely
related Ets proteins: PEA3, ERM (ETV5) and ER81 (ETV1)
[4–7]. PEA3 family members exhibit high sequence homology
within their ETS domains, and also have conserved regulatory
domains [6–14]. Several PEA3-interacting proteins have been
described that function as allosteric regulators and transcriptional
coactivators [9,15,16]. Additionally, both the activity and
expression of PEA3 factors can be regulated by receptor tyrosine
kinases through MAP kinase signaling [17,18]. PEA3 factors are
expressed in discrete patterns during embryogenesis, and contrib-
ute to branching morphogenesis in epithelia as well as to the
establishment of motor-neuronal circuitry [19–26]. Functional
overlap between individual PEA3 factors is suggested not only by
their overlapping target specificities, but also by the modest
phenotype of Pea3 knockout mice [27].
Substantial evidence implicates the PEA3 family in breast
neoplasia. Expression of all three family members has been
detected in human breast cancer cell lines, and strikingly high
expression levels have been identified in oncogene-induced breast
tumors in mice [28–34]. The reported frequency of PEA3
overexpression in human breast carcinomas ranges from 22–
76% [35–40]. Some studies have identified correlations with
clinicopathological parameters, including overexpression of hu-
man epidermal growth factor receptor 2 (HER2/neu) [35–37] and
poor prognosis [39], though none of these associations are
uniformly supported across studies. PEA3 overexpression has also
been observed in cancers of other organs, including the ovary,
lung and gastrointestinal tract [41–47], and associations between
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carcinoma, gastric cancer and colorectal carcinoma (CRC) have
been reported [44,46,47].
A key role for the PEA3 family in carcinogenesis is suggested not
only by these expression data, but also by the extensive list of
protumorigenic genes that can be transactivated by PEA3 proteins
[48]. Foremost among these are the matrix metallopeptidases
(MMPs), of which multiple family members are coordinately
regulated by PEA3 and AP-1 factors [42,49,50]. Additional PEA3
family target genes implicated in neoplasia include; urokinase
plasminogen activator (uPA), vimentin, cyclooxygenase-2 (COX-
2), Twist, MUC4, WT1, osteopontin, mammaglobin, cyclin D3
and HER2 [31,34,51–60]. Notably, PEA3 factor target genes are
frequently coordinately regulated by PEA3 factors in combination
with b-catenin and/or AP-1 factors [31,42,50,53,55,57,61].
Consistent with this, correlations have been observed between
expression of PEA3 and known target genes (e.g. MMP1, MMP7,
COX-2) in colorectal tumors [41,42,44,45], which characteristi-
cally exhibit increased b-catenin levels. Intriguingly, several of the
PEA3 targets identified thus far have established roles in epithelial-
mesenchymal transition (EMT), suggesting that PEA3 factors may
promote tumor progression through regulation of EMT
[51,55,62,63].
The expression and gene regulation data summarized above
argue for a protumorigenic role of PEA3 factors. Nevertheless,
several lines of evidence contradict this notion. In particular, the
demonstration of PEA3-mediated suppression of the HER2
promoter has engendered the hypothesis that PEA3 might have
tumor-suppressor function that could be leveraged for anticancer
gene therapy [64–66]. In support of this goal, PEA3 overexpres-
sion has been shown to inhibit the growth of HER2-overexpressing
breast and ovarian tumor xenografts in vivo [66,67], and to reduce
in vitro invasiveness of a cervical cancer cell line [68]. Additionally,
one study identified a positive association between increased
patient survival and PEA3 expression in human breast cancers
[38]. Intriguingly, the ability of dietary oleic acid to increase PEA3
expression and thereby repress HER2 has been proposed as a key
mechanism underlying the protective effect of the ‘‘Mediterranean
diet’’ with respect to breast cancer [69].
Controversy concerning the role of PEA3 factors in carcino-
genesis prompted us to further examine the role of this
transcription factor family in mammary neoplasia, using the
MMTV/Wnt1 mouse model in which tumor formation is driven
by mammary-targeted expression of a Wnt1 transgene. The utility
of this model was illustrated by our previous observation of
extremely high level Pea3 expression in tumors from MMTV/
Wnt1 mice [31], and was further supported by data from other
investigators establishing a correlation between expression of PEA3
and PEA3 target genes under conditions of Wnt/b-catenin
pathway activation [41,42,44,45]. Using a LacZ-based reporter
strain, Pea3
NLSlacZ, to detect endogenous Pea3 expression, we
confirm that Pea3 is selectively expressed in myoepithelial cells in
normal mammary gland [70], and demonstrate that Wnt1
expression induces selective expansion of the myoepithelial cell
compartment in non-tumorous mammary glands, accompanied by
an apparent increase in Pea3 expression. Consistent with this
observation of Wnt1-induced expansion of the basal cell layer, we
show that b-catenin/TCF signaling is strongly and selectively
activated in mammary myoepithelium in adult MMTV/Wnt1
mice. Early onset tumor formation in MMTV/Wnt1 mice is
significantly delayed by expression of a dominant-interfering PEA3
mutant, and expression of this dominant negative PEA3 transgene
is markedly reduced in tumors relative to non-tumorous mammary
tissues. Together these data suggest that PEA3 factors are
important contributors to Wnt1-induced breast neoplasia, and
thus strengthen the rationale for PEA3 family transcription factors
as anti-breast cancer targets.
Materials and Methods
Ethics Statement
All mice were housed in pathogen-free rooms in filter-topped
cages at the Laboratory Animal Research Center at The
Rockefeller University or at the New York Blood Center. These
facilities are accredited by the Association for Assessment and
Accreditation of Laboratory Animal Care, and operate in
accordance with Federal (PHS Policy on the Human Care and
Use of Animals, Guide for the Use and Care of Laboratory
Animals, Animal Welfare Act), State and local laws and
regulations. All mice were used in accordance with protocols
approved by the Institutional Animal Care and Use Committees of
either The Rockefeller University or the New York Blood Center.
Mice received food and water ad libitum.
Mouse Strains, Breeding, Tissue Harvesting and
Processing
The MMTV/Wnt1 strain expresses a mammary-targeted Wnt1
transgene under the control of the mouse mammary tumor virus
(MMTV) long terminal repeat. MMTV/Wnt1 females exhibit
hyperplastic mammary glands and develop palpable mammary
tumors between 4–12 months of age [71]. An MMTV/Wnt1
breeding colony was maintained by interbreeding MMTV/Wnt1
males, obtained from The Jackson Laboratory, with wildtype
females.
Pea3
NLSlacZ mice have a bacterial b-galactosidase (b-gal; lacZ)
expression cassette ‘‘knocked-in’’ to the endogenous Pea3 locus,
and express b-gal from the targeted allele in a pattern that mimics
the spatial and temporal expression of the endogenous Pea3 allele
[19,32,70]. This strain thus provides a useful reporter of Pea3
expression patterns in vivo. MMTV/Wnt1 males and Pea3
+/NLSlacZ
females were interbred, and female offspring of all four potential
genotypes were retained: wildtype (i.e. Pea3
+/+), MMTV/Wnt1,
Pea3
+/NLSlacZ, and bigenic MMTV/Wnt1, Pea3
+/NLSlacZ. Mammary
glands and tumors were harvested post-mortem and stained with
X-gal to detect b-gal activity, as previously described [72].
Abdominal (#4) mammary glands were wholemounted after
staining. Axillary (#3) mammary glands were fixed in formalin,
embedded in paraffin, and 8 mm tissue sections were counter-
stained with eosin.
The Axin2
NLSlacZ strain was employed as a reporter of in vivo b-
catenin/TCF signaling. Axin2 is upregulated in response to
canonical Wnt/ b-catenin signaling, and functions as a negative
feedback regulator [73,74]. Axin2
NLSlacZ mice have a b-gal
expression cassette ‘‘knocked-in’’ to the endogenous Axin2 locus,
and hence provide a useful reporter of in vivo b-catenin/TCF
pathway activation [74]. Axin2
+/NLSlacZ mice were interbred with
MMTV/Wnt1 animals and tissues were harvested and processed
as described for the Pea3
NLSlacZ experiment.
MMTV/DNPEA3En mice express a dominant interfering
mutant in which the repression domain from the Drosophila
melanogaster Engrailed (En) protein is appended to the C-terminal
DNA-binding domain of PEA3 [32]. Both MMTV/Wnt1 and
MMTV/DNPEA3En animals were maintained on an FVB strain
background. MMTV/Wnt1 males and MMTV/DNPEA3En
females were interbred to generate MMTV/Wnt1 (n=19) and
bigenic MMTV/Wnt1, MMTV/DNPEA3En (n=22) female
offspring. Test animals were palpated twice weekly to detect
mammary tumors, and the age at first tumor detection was
PEA3 Factors and Breast Cancer
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were 1 cm in diameter. Mammary glands and tumors were
harvested post-mortem, snap-frozen in liquid nitrogen, and stored
at 280uC.
Mouse Genotyping
Mice were genotyped by polymerase chain reaction (PCR) of
tail-tip-derived genomic DNA. The PCR primers used to detect
the Wnt1 transgene were as previously described [31]. Pea3
wildtype and Pea3
NLSlacZ alleles were detected using the following
primer pairs: Pea3,5 9-GGA ATC TTG GGC CTT GAG AAC
AGC-39 and 59-GTG TGA TGT ACA TAT GCC CTA ACC-39
(686 bp product); Pea3
NLSlacZ,5 9-CAG CCT CTG TTC CAC
ATA CAC TCC-39 and 59-TAG TAT CGC AGC GAG CGG
CTC AGC-39 (479 bp product). The DNPEA3En transgene was
detected using one primer each from the Pea3 gene and the
Engrailed gene: 59-TTG AAC CTG AAG AGG TTG CC-39 and
59-TGT GGA AAC TCA TGT CAC CG-39 (727 bp product).
The Axin2 wildtype allele was detected using the following primers:
Cs, 59-AAG CTG CGT CGG ATA CTT GAG A-39; and Cwt,
59-AGT CCA TCT TCA TTC CGC CTA GC-39 (493 bp
product). The Axin2
NLSlacZ allele was detected using Cs primer in
combination with a LacZ-specific primer 59-TGG TAA TGC
TGC AGT GGC TTG-39 (,400 bp product).
b-Catenin Immunohistochemistry
b-catenin immunohistochemistry (IHC) was performed as
previously described [75]. Briefly, after treating tissue sections
with hydrogen peroxide to block endogenous peroxidase activity,
sections underwent sodium citrate/microwave oven-based antigen
retrieval. Slides were incubated overnight with primary antibody
(anti-ß-catenin, Clone 14, BD Transduction Labs) and subse-
quently with secondary antibody for 1 hour (biotinylated horse
anti-mouse IgG, Vector Labs). Antigen was visualized using
Vectastain ABC reagent followed by 3,39-diaminobenzidine
staining, and a final hematoxylin counterstain. Duplicate slide
staining with primary antibody omitted was routinely performed
to provide a negative control.
Reverse Transcription-Coupled PCR (RT-PCR) Analysis
RT-PCR was used to compare gene expression in mammary
tissues harvested from five animals each that were MMTV/Wnt1,
MMTV/DNPEA3En and bigenic MMTV/Wnt1, MMTV/
DNPEA3En. Total RNA was prepared from resected, snap-frozen
mammary glands and tumors, and cDNA was generated by
reverse transcription as previously described [76]. ‘‘Mock cDNA’’
was generated by performing reactions in parallel with those used
to generate cDNA, omitting reverse transcriptase enzyme from the
reaction. PCR was performed using primers for the Wnt1 and
DNPEA3En transgenes, and for RNA Polymerase II (RPII) as a
normalization and quality control. Primer sequences were: Wnt1,
previously described [31]; DNPEA3En, 59-AAG GAG GAG GAA
AGC GAC TC-39 and 59-AGG AGA TGG CTG CTG AGT
TGG-39; RPII, 59-GCT TAC CAT GGA ACA GAT TGC TG-
39 and 59-CAC CTC TTC CTC CTC TTG CAT C-39. PCR
reaction products were fractionated on agarose gels and gel images
were captured using a BioRad Molecular Imager ChemiDoc XRS
System. No detectable PCR products were generated in reactions
using ‘‘mock cDNA’’. Band intensities were quantitated by analysis
on an Apple computer using the public domain NIH Image
program (developed at the U.S. National Institutes of Health and
available on the Internet at http://rsb.info.nih.gov/nih-image/).
Values obtained were normalized to those obtained for RPII. To
compare DNPEA3En expression in non-tumorous mammary
glands and mammary tumors from bigenic MMTV/Wnt1,
MMTV/DNPEA3En animals, the DNPEA3En signal was nor-
malized to the Wnt1 signal.
Statistical Analysis
Kaplan-Meier curves of tumor-free survival in MMTV/Wnt1
and bigenic MMTV/Wnt1, MMTV/DNPEA3En cohorts were
compared using a one-tailed log-rank test (Prism 4.0 for
Macintosh, GraphPad Software Inc., San Diego, CA). Early onset
tumor latency in the two cohorts was compared by censoring
survival data at 130 days. Simple independent one-tailed t-tests
were performed to effect pairwise comparisons of gene expression
between groups (Microsoft Excel 2004 for Mac, Microsoft
Corporation, Redmond, WA).
Results
Wnt1 Expression in Mouse Mammary Tissues Drives
Expansion of the Pea3-Expressing Myoepithelial
Population
We have previously identified Pea3 as being extremely highly
expressed in mammary tumors from MMTV/Wnt1 transgenic
mice. Specifically, Northern blotting revealed that Pea3 was
expressed at a similar level to the highly expressed glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) gene utilized as a normalization
control [31]. We interpreted this high level Pea3 expression as
potentially indicative of a protumorigenic role for Pea3, particu-
larly given that Pea3 positively regulates transcription of multiple
proneoplastic genes [31,34,42,48–60]. However, our earlier study
did not establish whether Pea3 is upregulated prior to the
formation of frank tumors, since Northern blotting was insuffi-
ciently sensitive to detect Pea3 transcripts in mammary glands
prior to tumor development from either wildtype or MMTV/
Wnt1 mice. Therefore, in the present study we utilized a reporter
strain, Pea3
NLSlacZ, in which a bacterial b-galactosidase expression
cassette is inserted into the endogenous Pea3 allele [19,32,70], to
assess Pea3 expression levels in non-tumorous mammary tissue.
The Pea3
NLSlacZ reporter allele has been shown to recapitulate the
temporospatial expression patterns previously described for the
endogenous Pea3 allele, and thus appears to provide faithful and
sensitive reporting of expression of the endogenous Pea3 gene
[19,32,70].
Pea3
+/NLSlacZ mice were crossed to MMTV/Wnt1 mice, and
mammary glands from female offspring of all four resultant
genotypes were stained with X-gal to detect b-gal activity. Distinct
staining of epithelial structures was apparent in wholemounted
mammary glands from Pea3
+/NLSlacZ females and bigenic MMTV/
Wnt1, Pea3
+/NLSlacZ females, but was not observed in tissues from
animals lacking the Pea3
NLSlacZ allele (Figure 1). Gross examina-
tion of X-gal-stained wholemounted glands from age-matched
Pea3
+/NLSlacZ and bigenic MMTV/Wnt1, Pea3
+/NLSlacZ virgin
females suggested that Wnt1 expression was associated with
increased signal intensity (Figure 2A). Microscopic examination
of both wholemounts and tissue sections revealed that b-gal
activity, and hence Pea3 expression, was restricted predominantly
to the myoepithelial cells comprising the outer epithelial layer of
the mammary ducts (Figures 2B and C), as previously reported
[70]. Sporadic b-gal-positive nuclei were also evident in nerve
bundles within the mammary glands (data not shown). Unexpect-
edly, we observed that the number of Pea3-positive myoepithelial
cells was increased in Wnt1-expressing mammary ducts (Figures 2B
and C), suggesting that the myoepithelial compartment is
selectively amplified in response to Wnt1 expression. Additionally,
the signal intensity in individual myoepithelial cells appeared to be
PEA3 Factors and Breast Cancer
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+/NLSlacZ mammary
glands relative to that in Pea3
+/NLSlacZ samples (Figures 2B and C).
Pea3 Is Highly Expressed in MMTV/Wnt1 Tumor
Epithelium
The extremely high level of Pea3 expression in MMTV/Wnt1
mammary tumors rendered it technically challenging to reliably
achieve X-gal staining of tumor samples, due to rapid precipitation
of reaction product on the tissue surface. This problem was
partially overcome by cutting tumor tissue samples into multiple
slices prior to staining, and carefully sectioning the outermost face
in the plane of the gross slice. Using this approach, we found that
Pea3 expression was predominantly restricted to, and highly
expressed in, the tumor epithelium (Figure 2D), which contains
cells of both myoepithelial and luminal lineages [77–79].
Widespread expression throughout the tumor epithelium was
confirmed by in situ hybridization analysis (R Baker and LR Howe;
unpublished data).
b-Catenin/TCF Signaling Is Preferentially Activated in the
Myoepithelial Compartment in MMTV/Wnt1 Mammary
Glands
To further investigate the unexpected finding that the
myoepithelial compartment was selectively amplified in
MMTV/Wnt1 mammary glands, we sought to define which cell
types exhibit activation of the canonical Wnt/b-catenin signaling
pathway in response to Wnt1 transgene expression. Our first
approach was to perform b-catenin immunohistochemistry (IHC)
to visualize nucleocytoplasmic accumulation of b-catenin protein,
the hallmark of canonical Wnt signaling. As expected, b-catenin
protein was localized to the plasma membrane of epithelial cells in
wildtype mouse mammary glands, consistent with its role at the
adherens junction (Figure 3A). There was a marked increase in b-
catenin protein levels in premalignant mammary tissues from
MMTV/Wnt1 mice (Figure 3B). Not only was increased
membrane staining detected, but there was also substantial
accumulation of nucleocytoplasmic b-catenin protein. Notably,
the most robust staining was observed in the myoepithelial cell
layer (Figure 3B; black arrowhead).
As a corollary approach, the pattern of expression of a b-
catenin/TCF-responsive gene, Axin2, was compared in wildtype
and Wnt1-expressing mammary glands using the Axin2
NLSlacZ
reporter strain. Transcriptional activation of Axin2 appears to be a
widespread, if not ubiquitous, response to canonical Wnt/b-
catenin signaling [73,74], and hence Axin2 transcripts are
increasingly used as a convenient readout of b-catenin/TCF
pathway activation. The Axin2
NLSlacZ mouse strain has a b-gal
expression cassette ‘‘knocked-in’’ to the endogenous Axin2 locus,
and thus provides a useful tool for visualizing b-catenin/TCF
signaling in vivo [74]. MMTV/Wnt1 mice were crossed with
Figure 1. The Pea3
NLSlacZ strain acts as a reporter of in vivo Pea3
expression in mammary glands. Abdominal (#4) mammary glands
were harvested from female mice that were wildtype (WT), MMTV/Wnt1,
Pea3
+/NLSlacZ (Pea3lacZ), and bigenic MMTV/Wnt1, Pea3
+/NLSlacZ (MMTV/
Wnt1, Pea3lacZ). Mammary glands were stained with X-gal as previously
described [72] and wholemounted. Staining of epithelial structures was
observed in mammary glands from Pea3
+/NLSlacZ females and bigenic
MMTV/Wnt1, Pea3
+/NLSlacZ females, but not in tissues from wildtype or
MMTV/Wnt1 animals.
doi:10.1371/journal.pone.0008854.g001
Figure 2. Wnt1 expression in mammary tissues drives expansion of the Pea3-expressing myoepithelial population. Mammary tissues
were harvested from age-matched virgin female littermates and stained with X-gal. (A) Wholemounted glands (10 weeks old)–entire gland. (B)
Wholemounted glands (30 weeks old) viewed at 106magnification (inset, enlargement of boxed area). (C) Mammary gland tissue sections (10 weeks
old), counterstained with eosin, viewed at 406magnification. (D) Tumor tissue sections, counterstained with eosin, viewed at 406magnification. b-
gal activity, indicative of Pea3 expression, was detected primarily in myoepithelial cells in normal mammary glands. The frequency of Pea3-expressing
cells was increased in Wnt1-expressing mammary glands, and there was an apparent increase in signal intensity on a per cell basis. Pea3 was widely
expressed throughout the tumor epithelium in MMTV/Wnt1 mammary tumors.
doi:10.1371/journal.pone.0008854.g002
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+/NLSlacZ animals, and tissues from virgin female offspring of
the four resulting genotypes were stained with X-gal. As in the
Pea3lacZ experiment described above, b-gal activity was undetect-
able in mammary glands from wildtype or MMTV/Wnt1 animals
(data not shown). In contrast, b-gal signal was detected in
adipocytes throughout the fat pad of mammary glands from both
Axin2
+/NLSlacZ mice and bigenic MMTV/Wnt1, Axin2
+/NLSlacZ
littermates (Figure 4A). Similar observations were also made using
two additional TCF reporter strains (BAT-gal and TOPGAL; S
Takayama, AP Salmon and LR Howe; unpublished data)
suggesting that there may be constitutive Wnt/b-catenin signaling
in mammary adipocytes. However, consistent with the lack of
nucleocytoplasmic b-catenin in wildtype mammary epithelium
(Figure 3A), no b-gal activity was detected in the mammary
epithelium of Axin2
+/NLSlacZ mice in the absence of the Wnt1
transgene (Figures 4A and C; Axin2lacZ). Positively staining
fibroblast nuclei were observed in the connective tissue peripheral
to the mammary epithelium, but no staining was detected in the
luminal or myoepithelial cells (Figure 4C; Axin2lacZ), indicating
that there is little or no active Wnt/b-catenin signaling in the
mammary epithelium at this stage. This contrasts with the robust
myoepithelial staining observed in Pea3
+/NLSlacZ mammary gland
in the absence of Wnt1 expression (Figures 4B and D), and thus
suggests that Pea3 expression in normal mammary gland may be
regulated by non-Wnt signals.
Expression of the Wnt1 transgene induced profound activation
of Axin2lacZ expression, a surrogate for b-catenin/TCF signaling.
Mammary epithelium from bigenic MMTV/Wnt1, Axin2
+/NLSlacZ
mice exhibited intense X-gal staining which was most prominent
in the myoepithelial layer (Figures 4A and C; MMTV/Wnt1,
Axin2lacZ) [80]. Additionally, weaker but detectable staining was
observed in the inner, luminal epithelium in Wnt1-expressing
glands (Figure 4C). The finding of prominent lacZ expression in
the myoepithelial compartment in MMTV/Wnt1, Axin2
+/NLSlacZ
mammary glands is in striking concordance with the strong
nucleocytoplasmic b-catenin staining observed in this cell layer
(Figure 3B), and also mirrors the X-gal staining pattern in bigenic
MMMTV/Wnt1, Pea3
+/NLSlacZ mammary glands (Figures 2B and
C).
Dominant Negative PEA3 Suppresses Tumor Formation
in MMTV/Wnt1 Mice
Based on our observations of Pea3 upregulation in Wnt1-
expressing mammary glands and tumors [31] (Figure 2), we sought
to assess the requirement for PEA3 factors for Wnt1-induced
tumorigenesis. This question was addressed using a previously
generated dominant negative transgenic mouse strain MMTV/
DNPEA3En [32]. The DNPEA3En allele encodes a fusion protein
Figure 3. Wnt1 expression in mouse mammary glands induces
profound b-catenin accumulation in the myoepithelial com-
partment. Mammary gland tissue sections from virgin female mice (10
weeks old) were subjected to b-catenin IHC as previously described [75]
and counterstained with hematoxylin. As a control, serial sections were
stained in parallel omitting primary antibody (right-hand panels). (A)
Wildtype. (B) MMTV/Wnt1. Weak staining of membrane-localized b-
catenin was observed in wildtype epithelium. Vascular structures were
clearly evident in control slides stained with secondary antibody alone
(red arrowhead). Profound increases in b-catenin protein levels were
observed in MMTV/Wnt1 epithelium, including both increased mem-
brane signal as well as b-catenin accumulation in the cytoplasm and
nucleus. Cells in the myoepithelial compartment exhibited the
strongest b-catenin signal (black arrowhead).
doi:10.1371/journal.pone.0008854.g003
Figure 4. b-catenin/TCF signaling activity revealed using
Axin2
NLSlacZ mice mirrors nucleocytoplasmic b-catenin accumu-
lation. Abdominal (#4) mammary glands were harvested from fe-
male mice that were Axin2
+/NLSlacZ (Axin2lacZ) or bigenic MMTV/Wnt1,
Axin2
+/NLSlacZ (MMTV/Wnt1, Axin2lacZ), and were stained with X-gal as
previously described [72]. Pea3
+/NLSlacZ (Pea3lacZ) samples were also
included for comparison. (A) Wholemounted glands (11 weeks old),
viewed at 106magnification. (B) Wholemounted gland from Pea3lacZ
virgin female stained in parallel with the specimens in Panel A, viewed
at 106 magnification. (C) Mammary gland tissue sections (11 weeks
old), counterstained with eosin, viewed at 406 magnification. (D)
Mammary gland tissue section from Pea3lacZ virgin female (10 weeks
old), counterstained with eosin, viewed at 406 magnification. b-gal
activity was detected in adipocytes throughout the mammary fat pad
from both Axin2
+/NLSlacZ and bigenic MMTV/Wnt1, Axin2
+/NLSlacZ mice.
Additionally, in Axin2
+/NLSlacZ mammary gland, cells in the connective
tissue peripheral to the mammary epithelium stained positive, but no
staining was detected in the myoepithelial or luminal cells. Wnt1
expression induced robust b-gal activity, indicative of b-catenin/TCF
signaling, in the myoepithelial compartment, with weaker but
detectable signal in the luminal epithelium.
doi:10.1371/journal.pone.0008854.g004
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protein appended to the PEA3 C-terminus, which encompasses
the DNA-binding domain. The resultant mutant protein lacks the
PEA3 activation domain, and hence functions as a dominant
negative by binding to cognate PEA3 sites and repressing
transcription through the En repressor domain. This construct
has been shown to antagonize transcriptional activation by all
three PEA3 family members; PEA3, ERM, and ER81 [32], which
have overlapping target specificity. This is important because all
three PEA3 family proteins are expressed in MMTV/Wnt1
mammary tumors [31]. Use of the DNPEA3En dominant negative
allele circumvents potential functional redundancy between the
PEA3 family proteins, and thus offers a more robust approach
than a gene knockout strategy targeting individual PEA3 factors.
Conversely, one caveat with respect to this strategy is potential lack
of specificity of DNPEA3En. However, although the spectrum of
activity of this dominant-interfering PEA3 allele is not fully
defined, it fails to alter expression from the MMTV promoter [32],
which contains an Ets-binding site regulated by the Ets protein
GABP-a, indicating that only a subset of Ets factors are susceptible
to DNPEA3En-mediated repression.
To examine the effect of dominant negative PEA3 on Wnt1-
driven tumorigenesis, we compared tumor latency in MMTV/
Wnt1 and bigenic MMTV/Wnt1, MMTV/DNPEA3En virgin
females, generated by interbreeding MMTV/Wnt1 mice with
MMTV/DNPEA3En animals. Expression of the dominant-
interfering PEA3 mutant significantly delayed the formation of
early onset tumors in MMTV/Wnt1 mice (Figure 5A; P=0.03).
To exclude the possibility that this effect was due to DNPEA3En-
mediated suppression of expression of the tumor-driving Wnt1
oncogene, Wnt1 expression was compared in MMTV/Wnt1 and
bigenic MMTV/Wnt1, MMTV/DNPEA3En tissues. Co-expres-
sion of MMTV/DNPEA3En did not significantly decrease Wnt1
expression, assayed by RT-PCR, in either mammary glands or
tumors (Table 1). Thus this experiment demonstrates that
dominant negative PEA3 attenuates Wnt1-induced mammary
neoplasia.
The median time to tumor formation was 145 days in MMTV/
Wnt1 mice compared to 192 days in those animals also bearing the
DNPEA3En transgene. However, the Kaplan-Meier survival
curves intersected at 274 days (Figure 5B), suggesting that tumors
were ultimately able to ‘‘escape’’ suppression mediated by
dominant negative PEA3. One potential explanation for this
escape phenomenon is loss of expression of the DNPEA3En
transgene. To investigate this possibility, expression levels of the
DNPEA3En transgene in mammary glands and tumors were
measured by RT-PCR. The DNPEA3En transgene is expressed
from the MMTV promoter, which is primarily active in epithelial
cells in mouse mammary tissues. MMTV-regulated transcripts can
appear artificially elevated in tumors relative to premalignant
mammary gland when expression is normalized to a ‘‘housekeep-
ing’’ gene expressed in both epithelial and stromal compartments
because the ratio of epithelium to stroma is increased in tumors
compared with non-tumorous mammary glands. To control for
this potential artefact in measuring DNPEA3En transgene
expression, DNPEA3En levels were normalized to those of the
Wnt1 transgene, which is also expressed from the MMTV
promoter. Strikingly, the DNPEA3En:Wnt1 expression ratio was
substantially reduced in mammary tumors relative to non-
tumorous mammary glands from bigenic MMTV/Wnt1,
MMTV/DNPEA3En mice (Figure 6; P=0.01). These data
strongly suggest that suppression of DNPEA3En expression is a
prerequisite for tumor formation in bigenic MMTV/Wnt1,
MMTV/DNPEA3En animals, and thus provide additional
Figure 5. The dominant-interfering DNPEA3En transgene
suppresses early onset tumor formation in MMTV/Wnt1 mice.
Tumor latency was compared in two cohorts of virgin female mice,
MMTV/Wnt1 (red squares; n=19) and bigenic MMTV/Wnt1, MMTV/
DNPEA3En (blue diamonds; n=22), generated by interbreeding MMTV/
Wnt1 males with MMTV/DNPEA3En females. (A) Formation of early
onset tumors was substantially retarded by expression of the dominant-
interfering DNPEA3En transgene (P=0.03, log-rank test). Survival data
were censored at 130 days to compare early onset tumor formation (B)
The overall rate of tumor formation was similar in both cohorts,
suggesting that tumors were ultimately able to escape from DNPEA3En-
mediated tumor suppression (P=0.39, log-rank test).
doi:10.1371/journal.pone.0008854.g005
Table 1. Wnt1 transgene expression is not significantly
altered by coexpression of DNPEA3En.
Tissue Type Genotype
Wnt1 Transgene Expression
a
(Mean 6 SD) P
b
Mammary
gland
MMTV/Wnt1 1.2760.64 -
MMTV/Wnt1, MMTV/
DNPEA3En
0.9560.49 0.11
Mammary
tumor
MMTV/Wnt1 1.8161.09 -
MMTV/Wnt1, MMTV/
DNPEA3En
1.5260.71 0.30
Wnt1 transcripts were assayed by RT-PCR in mammary glands and tumors from
MMTV/Wnt1 and bigenic MMTV/Wnt1, MMTV/DNPEA3En animals (n=5 per
group). Wnt1 transcript levels were normalized to RNA Polymerase II (RPII) as an
internal control.
aNormalized to RPII.
bP value obtained by comparison of values in MMTV/Wnt1 and bigenic MMTV/
Wnt1, MMTV/DNPEA3En tissues, using a one-tailed t-test.
doi:10.1371/journal.pone.0008854.t001
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mammary tumorigenesis. Interestingly, a similar phenomenon was
reported by Shepherd et al. (2001) who crossed the DNPEA3En
transgenic with MMTV/neu mice and identified reduced expres-
sion of the DNPEA3En transgene in tumors relative to mammary
glands [32]. The molecular mechanism underlying loss of
DNPEA3En expression was not identified, but could potentially
involve loss of the transgene from the genomic DNA or epigenetic
silencing of the transgene locus.
Discussion
We and others have shown that Pea3 is highly expressed in
mouse breast tumors, and PEA3 overexpression also occurs in
human breast carcinomas [30–33,35–40,81]. Furthermore, Pea3
activates transcription of multiple neoplasia-associated genes,
including MMP genes, COX-2, Twist, osteopontin, uPA, vimentin,
MUC4, WT1, mammaglobin, cyclin D3 and HER2 [31,34,42,48–60].
For example, we have shown PEA3 to be a potent activator of
COX-2 transcription, and in turn have shown Cox-2 to be an
important contributor to HER2/neu-induced mammary neoplasia
and angiogenesis in mouse models [31,76,82]. Nevertheless, other
investigators have argued in favor of PEA3 functioning as a tumor
suppressor, based in part on the ability of high level PEA3
expression to suppress HER2 promoter activity in vitro and HER2-
expressing tumor growth in vivo [64,66,67,69]. Consistent with a
tumor-promoting function for PEA3, one study identified a
positive association between increased patient survival and PEA3
expression in human breast cancers [38].
In order to further assess the role of PEA3 factors in mammary
tumorigenesis, we chose a model in which breast neoplasia was not
driven by HER2/neu overexpression. We employed the MMTV/
Wnt1 strain because we had previously established that MMTV/
Wnt1 tumors exhibit robust Pea3 expression [31]. The evidence
presented here suggests a protumorigenic role for PEA3 factors in
Wnt1-induced mammary neoplasia. Specifically, the dominant-
interfering mutant DNPEA3En suppressed early onset tumor
formation in MMTV/Wnt1 mice (Figure 5A), and DNPEA3En
expression was markedly suppressed in those tumors that did
develop in bigenic MMTV/Wnt1, MMTV/DNPEA3En animals
(Figure 6). These data, which support a positive role of PEA3
factors in breast neoplasia, are consistent with those obtained by
other groups using a variety of approaches. Several studies have
shown that enhanced invasiveness, cell cycle progression and
tumorigenicity can be conferred by overexpressing PEA3 in breast
or lung cancer cell lines [43,56,83]. Conversely, suppressing the
expression or activity of PEA3 factors has been shown to reduce
proliferation and invasiveness of cancer cell lines in culture, and to
decrease in vivo tumorigenesis [32,48,84]. Furthermore, RNAi-
mediated knock-down of Pea3 in mouse mammary tumor cells
leads to decreased expression of multiple PEA3 gene targets with
established proneoplastic roles, including Cox-2, vimentin, Cyclin D3,
HER2/neu and several MMP genes [48]. Of note, positive
correlations between poor prognosis and PEA3 overexpression
have been identified in cancers of several tissue sites including
carcinomas of the breast, ovary, stomach and CRC [39,44,46,47].
In aggregate, these data support the potential therapeutic utility of
targeting PEA3 factors.
Our data provide a novel proof-of-principle that neoplasia
resulting from activation of Wnt/b-catenin signaling can be
attenuated by suppressing Ets factor activity. This finding may also
be relevant in the context of colorectal cancer, which is frequently
driven by mutational activation of the Wnt/b-catenin pathway.
Importantly in this respect, PEA3 factor overexpression is
prevalent both in human colorectal cancers and in intestinal
tumors from mouse CRC models [41,42,44,45]. Thus, we predict
that targeting PEA3 factors may also be of therapeutic benefit for
colorectal cancer patients.
Intriguingly, the interrelationship between Wnt/b-catenin
signaling and PEA3 may not be restricted to neoplasia, but may
also be important during normal mammary morphogenesis.
Potential functional interaction between PEA3 and Wnt signaling
during postnatal mammary development is suggested by the
overlapping phenotypes elicited by Pea3 nullizygozity and by
genetic ablation of LRP5 (low density lipoprotein receptor related
protein 5), a key component of the Wnt receptor complex. Thus,
both Pea3-null and LRP5-deficient mice exhibit a delay in terminal
end-bud formation and regression during mammopoiesis [70,85].
In addition to determining the role of PEA3 factors in Wnt1-
induced tumorigenesis, we also sought to characterize the effect of
Wnt1 on Pea3 expression in non-tumorous mammary glands.
Analysis of the LacZ-based reporter strain Pea3
NLSlacZ revealed an
apparent increase in intensity of Pea3 expression in mammary
myoepithelial cells in response to Wnt1 (Figure 2). Additionally,
this experiment revealed an unanticipated consequence of Wnt1
expression in mouse mammary gland. Specifically, Wnt1 stimu-
lates expansion of the myoepithelial compartment prior to tumor
formation (Figure 2). Several groups have previously characterized
MMTV/Wnt1 tumors as containing both myoepithelial and
luminal epithelial cells, based on the presence of discrete cell
populations exhibiting myoepithelial and luminal markers, and
have interpreted this as evidence that Wnt1 acts on multipotent
progenitor cells in mouse mammary glands [77–79]. Furthermore,
Wnt1-induced mammary hyperplasia has been theorized as
resulting from accumulation of relatively undifferentiated progen-
itor and transit-amplifying cells [86]. The observation that Wnt1
induces specific amplification of the myoepithelial, or basal,
compartment in Wnt1-expressing mammary gland prior to tumor
formation suggests that these putative Wnt1-responsive progenitor
cells may reside in the basal cell layer.
To further investigate the observation that Wnt1 induces
amplification of the mammary myoepithelial compartment, we
characterized the cellular response profile to Wnt1 expression
using both b-catenin IHC and a b-catenin/TCF-responsive
Figure 6. DNPEA3En expression is markedly decreased in
tumors relative to mammary glands from MMTV/Wnt1, MMTV/
DNPEA3En mice. Expression levels of the Wnt1 and DNPEA3En
transgenes in mammary glands and tumors from bigenic MMTV/Wnt1,
MMTV/DNPEA3En mice were assayed by RT-PCR. The expression level of
DNPEA3En in each sample was normalized to that of Wnt1 in the same
sample to control for potential variations in epithelial content between
tumors and nontumorous mammary glands. The ratio of DNPEA3En
expression to Wnt1 expression was strikingly reduced in mammary
tumors relative to non-tumorous mammary glands (P=0.01, t-Test).
doi:10.1371/journal.pone.0008854.g006
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NLSlacZ. b-catenin immunostaining revealed a
profound increase in b-catenin protein in MMTV/Wnt1 mam-
mary glands relative to the modest membrane signal in wildtype
tissues (Figure 3). Of particular note, we observed intense
nucleocytoplasmic signal in the myoepithelial cell layer. Consistent
with this immunohistochemical staining pattern, there was
profound induction of the b-catenin/TCF-responsive reporter
Axin2
NLSlacZ in Wnt1-expressing mammary epithelium (Figure 4).
The strongest signal was evident in the basal layer, as recently
reported [80]. Additionally, we detected lower signal intensity in
the inner, luminal layer. However, no epithelial Axin2
NLSlacZ
activity was detected in adult mammary glands in the absence of
Wnt1 transgene expression. This contrasts with our findings of
Pea3 expression in mammary myoepithelium in the absence of
Wnt1, and suggests that Pea3 expression in normal adult mammary
gland is regulated by non-Wnt signals. Interestingly, b-catenin/
TCF signaling activity was observed in mammary adipocytes
irrespective of the presence of the Wnt1 transgene, as revealed by
expression of Axin2
NLSlacZ (Figure 4A and C) and also of other b-
catenin/TCF-responsive reporter alleles (BAT-gal and TOPGAL;
S Takayama, AP Salmon and LR Howe; unpublished data). The
significance of this observation is unclear since Wnt/b-catenin
signaling is well characterized as a negative regulator of
adipogenesis [87]. Nevertheless, it is clear that Wnt1 transgene
expression induces a profound b-catenin/TCF signaling response
in mammary myoepithelial cells, which mirrors the Pea3
NLSlacZ
staining pattern in MMTV/Wnt1 mammary glands (compare
Figures 3B and 4C with 2C). Together these datasets suggest that
the myoepithelial compartment is preferentially responsive to
Wnt1. The selective Wnt1-responsiveness of the myoepithelium,
and the fact that Wnt1 induces expansion of this cell layer, most
likely reflects restricted expression of functional Wnt receptor
complexes since LRP6 expression is limited to basal cells in adult
mouse mammary gland [88]. Consistent with these observations, a
basal gene signature has been identified in cells extracted from
MMTV/Wnt1 mammary carcinomas [89,90].
In aggregate these data suggest the MMTV/Wnt1 strain as a
potentially useful model of basal breast cancer in humans. The
basal subtype has recently become a focus of intense concern
because such tumors constitute a therapeutically intractable subset
of breast cancers [91–93]. Since mammary stem cells have been
hypothesized to reside in the basal layer, our observations also
support the notion that Wnt1 may stimulate expansion of the
mammary stem cell population [94,95]. Intriguingly, the endog-
enous Pea3 expression profiles that we have observed in mouse
mammary gland (Figures 1 and 2) and in the colonic crypt (data
not shown) are strikingly similar to those reported for the putative
stem cell marker gene Lgr5 [96], giving credence to the notion that
Pea3 expression may be enriched in stem cell compartments.
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